ASMB (Assembly Biosciences) Marketable Securities: $195.48 Mil (As of Mar. 2026)


ASMB Assembly Biosciences Inc ASMB
32 GF Score
Price $27.73
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences Marketable Securities?

Assembly Biosciences ASMB +3.93% 32 Marketable Securities is $195.48 Mil as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Assembly Biosciences's Marketable Securities for the quarter that ended in Mar. 2026 was $195.48 Mil.

Assembly Biosciences's annual Marketable Securities declined from Dec. 2023 ($110.41 Mil) to Dec. 2024 ($73.74 Mil) but then increased from Dec. 2024 ($73.74 Mil) to Dec. 2025 ($189.66 Mil).

Assembly Biosciences  (NAS:ASMB) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Assembly Biosciences Marketable Securities Related Terms

Assembly Biosciences Marketable Securities Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences Marketable Securities Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 101.00 39.19 110.41 73.74 189.66

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 67.62 50.97 210.02 189.66 195.48
ASMB
32GF Score
Assembly Biosciences Inc ASMB
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $195.48 Mil mean?
Assembly Biosciences (ASMB) has a Marketable Securities of $195.48 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Assembly Biosciences and its competitors.
Is Assembly Biosciences' Marketable Securities too high?
Assembly Biosciences' current Marketable Securities is $195.48 Mil. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' Marketable Securities compare to CTNM and PRTA?
Assembly Biosciences' Marketable Securities of $195.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current Marketable Securities is $195.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current Marketable Securities of $195.48 Mil. The current Marketable Securities is $195.48 Mil. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current Marketable Securities is $195.48 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score

Get the complete analysis for ASMB

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$27.73
Price